Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has signed its first distribution agreement for its Xenon MRI platform, with a specialist medical distributor in Taiwan.
The deal has been struck with Taiwan's Sumtage Enterprise Company, which has been introducing advanced medical equipment from overseas into its local market for the past 30 years.
Polarean CEO Christopher von Jako said the company will work with Sumtage to gain the local regulatory clearances necessary for commercial launch in Taiwan to pave the way for the innovative platform to be sold and used in Taiwan.
"Sumtage are highly experienced in selling cutting-edge medical technology in Taiwan, making them the ideal partner to help us expand access to our innovative Xenon MRI platform into this market," von Jako said.
"While our own sales team remains focused on expanding the number of user sites within the United States, I am pleased to see our first commercial entry into the Asia-Pacific region via a high-quality distributor, where we believe our platform can provide great benefit to pulmonary patients and their physicians."
The North Carolina-based company noted that Sumtage has a comprehensive portfolio of medical imaging and diagnostic technologies, and offers customers additional maintenance and clinical support service post-sale.
Sumtage general manager, Hui-Lin Su, said the distributor is "excited to work with Polarean to bring this groundbreaking Xenon MRI technology to Taiwan to help address lung diseases such as lung cancer, COPD, and asthma.
"The Polarean Xenon MRI platform enables advanced lung function assessments, allowing physicians to identify affected regions at earlier stages and facilitate timely treatment.
"We have already seen strong interest from leading academic medical centres, highlighting the significant potential of this technology to improve lung health in Taiwan."